Search: WFRF:(Hebert J. M.) > (2010-2014) > Icatibant, a New Br...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05370naa a2200985 4500 | |
001 | oai:lup.lub.lu.se:c47411d8-02ff-4eb4-8169-1470cf8f6fa4 | |
003 | SwePub | |
008 | 160401s2010 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/16778182 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa09063932 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Cicardi, M.4 aut |
245 | 1 0 | a Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema |
264 | 1 | c 2010 |
520 | a BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. The primary end point was the median time to clinically significant relief of symptoms. RESULTS A total of 56 and 74 patients underwent randomization in the FAST-1 and FAST-2 trials, respectively. The primary end point was reached in 2.5 hours with icatibant versus 4.6 hours with placebo in the FAST-1 trial (P=0.14) and in 2.0 hours with icatibant versus 12.0 hours with tranexamic acid in the FAST-2 trial (P<0.001). In the FAST-1 study, 3 recipients of icatibant and 13 recipients of placebo needed treatment with rescue medication. The median time to first improvement of symptoms, as assessed by patients and by investigators, was significantly shorter with icatibant in both trials. No icatibant-related serious adverse events were reported. CONCLUSIONS In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as compared with placebo in the other trial with regard to the primary end point. The early use of rescue medication may have obscured the benefit of icatibant in the placebo trial. (Funded by Jerini; ClinicalTrials.gov numbers, NCT00097695 and NCT00500656.) | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng |
700 | 1 | a Banerji, A.4 aut |
700 | 1 | a Bracho, F.4 aut |
700 | 1 | a Malbran, A.4 aut |
700 | 1 | a Rosenkranz, B.4 aut |
700 | 1 | a Riedl, M.4 aut |
700 | 1 | a Bork, K.4 aut |
700 | 1 | a Lumry, W.4 aut |
700 | 1 | a Aberer, W.4 aut |
700 | 1 | a Bier, H.4 aut |
700 | 1 | a Bas, M.4 aut |
700 | 1 | a Greve, J.4 aut |
700 | 1 | a Hoffmann, T. K.4 aut |
700 | 1 | a Farkas, H.4 aut |
700 | 1 | a Reshef, A.4 aut |
700 | 1 | a Ritchie, B.4 aut |
700 | 1 | a Yang, W.4 aut |
700 | 1 | a Grabbe, J.4 aut |
700 | 1 | a Kivity, S.4 aut |
700 | 1 | a Kreuz, W.4 aut |
700 | 1 | a Levy, R. J.4 aut |
700 | 1 | a Luger, T.4 aut |
700 | 1 | a Obtulowicz, K.4 aut |
700 | 1 | a Schmid-Grendelmeier, P.4 aut |
700 | 1 | a Bull, C.4 aut |
700 | 1 | a Sitkauskiene, B.4 aut |
700 | 1 | a Smith, W. B.4 aut |
700 | 1 | a Toubi, E.4 aut |
700 | 1 | a Werner, Sonjau Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)lung-swe |
700 | 1 | a Anne, S.4 aut |
700 | 1 | a Bjorkander, J.4 aut |
700 | 1 | a Bouillet, L.4 aut |
700 | 1 | a Cillari, E.4 aut |
700 | 1 | a Hurewitz, D.4 aut |
700 | 1 | a Jacobson, K. W.4 aut |
700 | 1 | a Katelaris, C. H.4 aut |
700 | 1 | a Maurer, M.4 aut |
700 | 1 | a Merk, H.4 aut |
700 | 1 | a Bernstein, J. A.4 aut |
700 | 1 | a Feighery, C.4 aut |
700 | 1 | a Floccard, B.4 aut |
700 | 1 | a Gleich, G.4 aut |
700 | 1 | a Hebert, J.4 aut |
700 | 1 | a Kaatz, M.4 aut |
700 | 1 | a Keith, P.4 aut |
700 | 1 | a Kirkpatrick, C. H.4 aut |
700 | 1 | a Langton, D.4 aut |
700 | 1 | a Martin, L.4 aut |
700 | 1 | a Pichler, C.4 aut |
700 | 1 | a Resnick, D.4 aut |
700 | 1 | a Wombolt, D.4 aut |
700 | 1 | a Fernandez Romero, D. S.4 aut |
700 | 1 | a Zanichelli, A.4 aut |
700 | 1 | a Arcoleo, F.4 aut |
700 | 1 | a Knolle, J.4 aut |
700 | 1 | a Kravec, I.4 aut |
700 | 1 | a Dong, L.4 aut |
700 | 1 | a Zimmermann, J.4 aut |
700 | 1 | a Rosen, K.4 aut |
700 | 1 | a Fan, W. -T.4 aut |
710 | 2 | a Lungmedicin, allergologi och palliativ medicinb Sektion II4 org |
773 | 0 | t New England Journal of Medicineg 363:6, s. 532-541q 363:6<532-541x 0028-4793 |
856 | 4 | u http://dx.doi.org/10.1056/NEJMoa0906393y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/1677818 |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa0906393 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view